SOLICITATION NOTICE
A -- PREVENT Cancer Preclinical Drug Development Program - Solicitation
- Notice Date
- 5/7/2018
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions-Treatment and Support Branch, Bldg 244, Room 112, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- N01CN77019-18
- Archive Date
- 7/6/2018
- Point of Contact
- Nicole Belanger, Phone: 3016248754, Mandie S. White, Phone: 301-624-8756
- E-Mail Address
-
belangern@mail.nih.gov, whitems@mail.nih.gov
(belangern@mail.nih.gov, whitems@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- RFP No. N01CN77019-18 PREVENT Cancer Preclinical Drug Development Program The purpose of this solicitation is to procure Research & Development services to support the PREVENT Program in the areas of (1) in vivo development/animal efficacy/biomarker development, (2) preclinical product development and CGMP manufacturing of biopharmaceutical agents, and (3) toxicology/pharmacology testing. In order to meet the demands for all services in a timely and proactive manner, the NCI intends to award contracts that provide a suite of technical task support services, using the Indefinite Delivery-Indefinite Quantity (IDIQ) contract mechanism. Under the IDIQ mechanism, the NCI will award Task Orders for specific activities that meet technical requirements tailored for each identified PREVENT project's needs. While the overall suite of services listed is comprehensive, the intent is to provide individual services on a case-by-case basis for a diverse collection of candidate agents, rather than carry a single candidate product through an entire preclinical development pathway. These services are intended to help investigators in various scientific disciplines obtain critical data needed to advance their agents further through the PREVENT pipeline, acquire additional funding from other sources, gain prospective partnerships (either for further development or to support Phase I trials), fulfill regulatory requirements, and/or complete studies needed to apply for an IND and enter a Phase I trial.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/N01CN77019-18/listing.html)
- Record
- SN04912661-W 20180509/180507230541-aef91bbe16e059988198a2db49046da1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |